You can't patent a product of nature, but companies routinely patent modified analogs, salts, delivery systems, and dosing regimens. Rapamycin, metformin, and the statins all started as natural molecules and became patentable. If gray-market peptides delivered on their claims, the same industry racing to develop GLP-1 variants would already be racing to develop them.